Full-Time

Director – Regulatory Labeling

Remote

Updated on 11/18/2024

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Senior, Expert

Remote in USA

Category
Risk & Compliance
Legal & Compliance
Requirements
  • Science based BS or MS degree. Advanced degree (MD, Ph D, PharmD) preferred
  • Seasoned regulatory professional with 10+ years of industry experience and extensive experience (at least 6 years) in global regulatory labeling
  • Thorough understanding of regulatory labeling requirements and strategic labeling planning
  • Direct experience leading labeling content development through regulatory submission and review process, participating in Health Authority negotiations resulting in product approval
  • Experience maintaining the CCDS and global labeling throughout the product lifecycle
  • Experience leading cross-functional teams and negotiating with internal and external stakeholders on labeling issues
  • Strong writing skills; able to process scientific data and effectively summarize into the appropriate detail for labeling content
  • Strong interpersonal and communication (written and verbal) skills
  • Fluency in English as business language, additional languages advantageous
  • Cardiovascular therapeutic area experience is desirable
Responsibilities
  • The Global Labeling Lead is responsible for leading the development of Company Core Data Sheets (CCDS) and global labeling content (focus on US, EU and Canada), as applicable across regions through collaboration with key internal stakeholders
  • Create and maintain regulatory compliant, competitive, and up to date CCDS for assigned key development projects and marketed products
  • Review worldwide labeling against the CCDS and facilitate and track implementation of changes to align with core content
  • Participate in label-related Health Authority negotiation meetings
  • Contribute to maintenance and updates of labeling processes
  • As a member of the Global Regulatory Team ensure timely implementation of global labeling changes in local product information that are consistent with the company's position defined in the CCDS and in compliance with local labeling regulations
  • Review final artwork to be implemented into production, including approval of all change requests for revised labeling for assigned products
  • Maintain knowledge of current rules and regulations governing global labeling activities
  • Participate in interpretation and implementation of key regional labeling regulations, guidelines, and best labeling practices, and align with global strategic plan

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, depending on the condition being treated. For example, they are working on drugs for heart failure, hypertrophic cardiomyopathy, amyotrophic lateral sclerosis, and spinal muscular atrophy. What sets Cytokinetics apart from competitors is their specific focus on muscle-related conditions and their extensive pipeline of drugs currently in clinical trials. The company's goal is to bring effective treatments to market that address the unmet needs of patients suffering from these debilitating diseases.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

2%

1 year growth

1%

2 year growth

15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful Phase III trial results for aficamten in treating obstructive hypertrophic cardiomyopathy (HCM) highlight the company's potential for market leadership in this area.
  • The $575M funding from Royalty Pharma ensures strong financial support for the commercial launch of aficamten and further R&D activities.
  • Recent investments and stock offerings indicate strong investor confidence and provide additional capital for growth and development.

What critics are saying

  • The late-stage biopharmaceutical market is highly competitive, with significant pressure to bring drugs to market quickly and efficiently.
  • Dependence on the success of clinical trials and regulatory approvals poses inherent risks, as any setbacks could delay commercialization and revenue generation.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle function improvement for cardiovascular and neuromuscular diseases, a niche area with high unmet medical needs.
  • The company has a robust pipeline of small molecule muscle activators and inhibitors, setting it apart from competitors with more generalized drug portfolios.
  • Strategic funding collaborations, such as the $575M deal with Royalty Pharma, provide significant financial backing for their R&D and commercialization efforts.

Help us improve and share your feedback! Did you find this helpful?